Key result
Emerging AF therapies target molecular mechanisms to prevent disease progression beyond standard rhythm control drugs.
Why the study?
Recent research has expanded understanding of molecular mechanisms in AF, prompting the active search for new antiarrhythmic therapies that prevent AF development and progression at the molecular level.
The review summarizes current guideline-directed management of atrial fibrillation and highlights ongoing research into novel molecular-targeted antiarrhythmic therapies.
Current antiarrhythmic use in atrial fibrillation should continue unchanged; leaves open translation of molecular targets into practice.
Atrial fibrillation (AF) is the most common heart rhythm disorder. According to current recommendations, the treatment of AF includes 3 main directions: "A" – the appointment of anticoagulant therapy with an increased risk of thromboembolic complications, "B" – control of arrhythmia symptoms, choice of a strategy for rhythm control or control of ventricular contractions, "C" – treatment of concomitant diseases and correction of risk factors. The rhythm control strategy includes performing cardioversion, prescribing long-term antiarrhythmic therapy, or performing radiofrequency catheter ablation. According to the latest recommendations of 2020, antiarrhythmic drugs of IC and III classes are currently used for pharmacological cardioversion of AF and long-term retention of sinus rhythm. The choice of a specific antiarrhythmic drug is based on its safety and effectiveness. â-Blockers, non-dihydropyridine calcium channel blockers and digoxin are used to control CHS. The results of modern research have significantly expanded our understanding of the molecular mechanisms underlying various forms of AF. Currently, the search for new drugs is actively underway that will allow preventing the development of AF and its progression at the molecular level.
No takes yet. Share an insight, caveat, or question.
Тарзиманова et al. (2024) conducted a review in Atrial fibrillation. Antiarrhythmic therapy was evaluated. Antiarrhythmic therapy for atrial fibrillation currently relies on class IC and III drugs for rhythm control, while emerging treatments target specific molecular mechanisms to prevent disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: